Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.31 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837680 | 0.99 | ADORA3 (0.34) | ADORA3SLC6A2SLC6A4CYP2D6HRH1 | |
| SCHEMBL6834018 | 0.91 | SLC6A2 (0.38) | ADORA3SLC6A2SLC6A4HRH1KCNH2 | |
| SCHEMBL6837706 | 0.90 | ADORA3 (0.36) | ADORA3SLC6A2SLC6A4SLC6A3EPHA2 | |
| SCHEMBL6838392 | 0.90 | SLC6A2 (0.37) | ADORA3SLC6A2SLC6A4HRH1KCNH2 | |
| SCHEMBL6837810 | 0.89 | ADORA3 (0.37) | ADORA3SLC6A2SLC6A4SLC6A3EPHA2 | |
| SCHEMBL6840005 | 0.86 | ADORA3 (0.35) | ADORA3HRH1NOS1NOS2 | |
| SCHEMBL6833816 | 0.85 | ADORA3 (0.37) | ADORA3HRH1NOS1NOS2NPC1 | |
| SCHEMBL6837682 | 0.85 | GRIN1 (0.35) | SLC6A2SLC6A4CYP2D6HRH1KCNH2 | |
| SCHEMBL6838736 | 0.85 | SSTR4 (0.38) | ADORA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6840155 | 0.84 | SSTR4 (0.38) | ADORA3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | ADORA3 3201/4885SLC6A2 4336/4885SLC6A4 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.